Literature DB >> 21719866

Further enhancement of facial appearance with a hydroquinone skin care system plus tretinoin in patients previously treated with botulinum toxin Type A.

Joel Schlessinger1, Jeffrey Kenkel, Philip Werschler.   

Abstract

BACKGROUND: A hydroquinone (HQ) skin care system has been designed for use in conjunction with nonsurgical procedures.
OBJECTIVE: The authors evaluate the efficacy of this system plus tretinoin for improving facial appearance in comparison to a standard skin care regimen in users of botulinum toxin Type A (BoNT-A).
METHODS: In this multicenter, randomized, investigator-masked, parallel-group study, 61 patients who received upper facial treatment with BoNT-A at a plastic surgery or dermatology clinic were randomly assigned to apply either the HQ system (cleanser, toner, proprietary 4% hydroquinone, exfoliant, and sunscreen) plus 0.05% tretinoin cream or a standard skin care regimen (cleanser, moisturizer, and sunscreen) for 120 days. Outcomes were assessed by the investigators and through a patient questionnaire.
RESULTS: Compared with standard skin care, the HQ system plus tretinoin resulted in significantly milder fine lines/wrinkles and hyperpigmentation at Days 30, 90, and 120 (p ≤ .05) and significantly superior overall ratings for each of nine patient assessments at Days 90 and 120 (p ≤ .05). A relatively greater proportion of patients using the HQ system plus tretinoin believed that their study treatment had further enhanced the improvements attained with BoNT-A (86% vs 8%). Both regimens were generally well tolerated.
CONCLUSIONS: Adjunctive use of the HQ system plus tretinoin can further enhance the improvements in facial appearance attained with BoNT-A. Applying the HQ system plus tretinoin offers multiple clinical benefits over standard skin care, including significantly greater improvements in fine lines/wrinkles and hyperpigmentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719866     DOI: 10.1177/1090820X11411579

Source DB:  PubMed          Journal:  Aesthet Surg J        ISSN: 1090-820X            Impact factor:   4.283


  4 in total

1.  Open-label treatment of moderate or marked melasma with a 4% hydroquinone skin care system plus 0.05% tretinoin cream.

Authors:  Michael Gold; Marta Rendon; Barry Dibernardo; Suzanne Bruce; Chere Lucas-Anthony; Joanne Watson
Journal:  J Clin Aesthet Dermatol       Date:  2013-11

Review 2.  New Uses of AbobotulinumtoxinA in Aesthetics.

Authors:  Joel Schlessinger; Erin Gilbert; Joel L Cohen; Joely Kaufman
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

3.  The Science and Theory behind Facial Aging.

Authors:  Jordan P Farkas; Joel E Pessa; Bradley Hubbard; Rod J Rohrich
Journal:  Plast Reconstr Surg Glob Open       Date:  2013-05-07

4.  A Comparative In Vivo Study on Three Treatment Approaches to Applying Topical Botulinum Toxin A for Crow's Feet.

Authors:  Yan Cao; Jian-Ping Yang; Xiao-Gang Zhu; Jie Zhu; Hong-Qin Chang; Sheng-Hua Guo; Dan Luo; Bing-Rong Zhou
Journal:  Biomed Res Int       Date:  2018-07-03       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.